Dyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
03/03/2025 14:31
Dyne Therapeutics Inc DYN.OQ reported a quarterly adjusted loss of 88 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.09. The mean expectation of twelve analysts for the quarter was for a loss of 96 cents per share. Wall Street expected results to range from $-1.23 to -73 cents per share. Reported revenue was zero; analysts expected zero. Dyne Therapeutics Inc's reported EPS for the quarter was a loss of 88 cents. The company reported a quarterly loss of $89.54 million. Dyne Therapeutics Inc shares had fallen by 42.2% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 0.2% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Dyne Therapeutics Inc is $50.00 This summary was machine generated from LSEG data March 3 at 02:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.96 | -0.88 | Beat |
| Sep. 30 2024 | -0.71 | -0.96 | Missed |
| Jun. 30 2024 | -0.72 | -0.70 | Beat |
| Mar. 31 2024 | -0.80 | -0.81 | Missed |